|
|
|
| Resistance variation trend and clinical character of multi-drug resistant Acinetobacter baumannii |
| CHEN Haohao1 CAI Xiaorui2 TANG Danling1 CAI De1 WEI Duncan1 LIN Yun3 |
1.Department of Pharmacy, the First Affiliated Hospital of Shantou University Medical College, Guangdong Province, Shantou 515041, China;
2.Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Guangdong Province, Shantou 515041, China;
3.Department of Pharmacy, Shantou Central Hospital, Guangdong Province, Shantou 515041, China |
|
|
|
Abstract Objective To analyze the resistance trend of multi-drug resistant Acinetobacter baumanii (MDR-AB) of the inpatients in the First Affiliated Hospital of Shantou University Medical College (“our hospital” for short), in order to provide reference for clinical treatment. Methods Retrospective analysis was used for this study. The clinical data of 902 inpatients with MDR-AB infection from 2013 to 2016 in our hospital were collected. The clinical data such as sex, age, department, clinical diagnosis and drug sensitivity test results were collected. Chi-square test and Pearson were used for statistical analysis. Results The proportion of male to female was about 7 to 3. Majority of the cases were middle-aged and aged, of which over 40% were ＞65 years old, and about 50% were 18-65 years old. Sputum specimen was mainly, which accounted for over 80%. About 10% of the total specimen were blood, urine and secretions. The cases mainly distributed in Department of ICU, Neurosurgery and Neurology. The proportion of Department of ICU and Neurosurgery showed a decreasing trend, during the period from 2013 to 2016, whose proportion were reduced from 43.61% and 36.84% to 23.05% and 25.15% respectively. On the contrary, the proportion of Department of Neurology, Respiratory Medicine and Neonates showed increasingly, whose proportion were increased from 6.77%, 4.51% and 0.75% to 10.48%, 7.49% and 5.69% from 2013 to 2016. The average resistance rate of MDR-AB to Tigecycline and Polymyxin B were below 10%, to Levofloxacin and Cefoperazone/Sulbactan were close to 50%, to the other antibacterials which were analyzed in this study were above 50%, more seriously, ten of these drugs whose resistance were over 80%. In addition, the proportion of MDR-AB increased significantly (P < 0.05). The results of Pearson correlation analysis showed that resistance rates of Ceftriaxone, Cefepime, Gentamycin, Tobramycin and Ciprofloxacin were highly positive correlated with the trend of Imipenem resistance (P < 0.05). Conclusion The isolated MDR-AB are mainly located in Department of ICU, Neurosurgery and Neurology. The resistance rate of commonly used antibiotics to MDR-AB are severe. Rational application of antibacterial drugs and strengthening management of multiple-drug resistant bacteria should be implemented.
|
|
|
|
|
|
[1] Gonzalez-Villoria AM，Valverde-Garduno V. Antibiotic-resistant Acinetobacter baumannii increasing success remains a challenge as a nosocomial pathogen [J]. J Pathog， 2016，2016（4）：1-10.
[2] Bassetti M，Ginocchio F，Mikulska M. New treatment options against gram-negative organisms [J]. Critical Care，2011，15（2）：215-223.
[3] 陶建萍，毛得斌.多重耐药鲍曼不动杆菌感染的危险因素及预后分析[J].广西医学，2017，39（1）：113-115.
[4] Uwingabiye J，Lemnouer A，Baidoo S，et al. Intensive care unit-acquired Acinetoacter baumannii infections in a Moroccan teaching hospital：epidemiology，risk factors and outcome [J]. Germs，2017，7（4）：193-205.
[5] 胡付品，郭燕，朱德妹，等.2016年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志，2017，17（5）：481-491.
[6] 廉婕，蔡博涛，雷鑫星.耐碳青霉烯类鲍曼不动杆菌耐药性及感染危险因素分析[J].中国医药导报，2016，13（4）：109-112.
[7] Howard A，O′Donoghue M，Feeney A，et al. Acinetobacter baumannii：An emerging opportunisti pathogen [J]. Virulence，2012，3（3）：243-250.
[8] 张小江，张辉，杨启文，等.世界卫生组织关注的临床重要细菌耐药变迁：北京协和医院10年数据分析[J].协和医学杂志，2018，9（1）：48-53.
[9] 张蓉，陈倩，祝丙华，等.2013-2016年老年医院鲍曼不动杆菌临床分布及耐药性[J].中国感染控制杂志，2018， 17（2）：103-106.
[10] 胡向国，余广超，刘菊珍.2010-2016年我院鲍曼不动杆菌的耐药性分析[J].中国抗生素杂志，2017，42（7）：592-595.
[11] 高健，李子民，张特立，等.2012-2015年鲍曼不动杆菌耐药性变迁及抗菌药物选择[J].中国医院药学杂志，2017， 37（6）：562-565.
[12] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing [S]. 2012：M100-S22.
[13] 贾会学，殷环，吴安华，等.新生儿重症监护病房医院感染流行病学多中心研究[J].中国感染控制杂志，2015， 14（10）：649-653.
[14] Kumar A，Randhawa VS，Nirupam N，et al. Risk factors for carbapenem-resistant Acinetobacter baumanii blood stream infections in a neonatal intensive care unit，Delhi，India [J]. J Infect Dev Countr，2014，8（8）：1049-1054.
[15] 廖旭东.新生儿血流感染病原菌分布及耐药性新趋势研究[J].中国医药导报，2014，11（11）：109-112.
[16] 房晓祎，黄晓玲，麦瑞芝，等.重症监护病房新生儿肺炎常见致病菌分析[J].汕头大学医学院学报，2017，30（2）：99-101.
[17] 陈佰义，何礼贤，胡必杰，等.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志，2012，92（2）：76-85.
[18] Yang ZW，Zhang YL，Yuan M，et al. Clinical treatment of pandrug-resistant bacterial infection consulted by clinical pharmacist [J]. Saudi Pharm J，2015，23（4）：377-380.
[19] Iosifidis E，Antachopoulos C，Tsivitanidou M，et al. Differential Correlation Between Rates of Antimicrobial Drug Consumption and Prevalence of Antimicrobial Resistance in a Tertiary Care Hospital in Greece [J]. Infect Cont Hosp Ep，2008，29（7）：615-622.
[20] 吴萌萌，李雯，陈芸.舒巴坦对鲍曼不动杆菌突变选择窗与外膜蛋白相关性研究[J].中国医药导报，2015，12（31）：48-53. |
|
|
|
